Literature DB >> 19937400

Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature.

Nikolaos S Salemis1, Stavros Gourgiotis, Evangelos Tsiambas, Grigorios Karagkiouzis, Georgios Nakos, Vasilios Karathanasis.   

Abstract

INTRODUCTION: Diffuse large B cell lymphoma is the most commonly diagnosed non-Hodgkin's lymphoma, whereas lymphoma is the most common cause of mesenteric masses. We herein present a very rare case of a young male patient with a giant diffuse large B cell lymphoma of the mesentery that was incidentally diagnosed during his admission for a road traffic accident.
MATERIALS AND METHODS: At laparotomy, a huge tumor measuring 18 x 14 x 10 cm was found originating from the jejunal mesentery. Despite the giant size of the tumor, the patient was completely asymptomatic. After complete surgical recection with clear margins, he recieved six cycles of CHOP chemotherapy in the pre-rituximab era. RESULTS AND DISCUSSION: He remained disease-free 2 years after surgery, but unfortunately, he relapsed with disseminated disease and died 6 months later. Mesenteric lymphomas may remain asymptomatic until they reach a large size. The presence of a bulky mesenteric mass is a poor prognostic indicator.
CONCLUSION: Although chemotherapy is the treatment of choice for diffuse large B cell lymphoma, in some cases radical surgery has a role in establishing a definitive diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937400     DOI: 10.1007/s12029-009-9114-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  21 in total

Review 1.  The sandwich sign.

Authors:  Seth M Hardy
Journal:  Radiology       Date:  2003-03       Impact factor: 11.105

2.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  Prognostic factors in diffuse large B-cell lymphoma.

Authors:  Nozomi Niitsu
Journal:  Intern Med       Date:  2006-04-03       Impact factor: 1.271

4.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

5.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.

Authors:  M Oguchi; H Ikeda; K Isobe; S Hirota; M Hasegawa; K Nakamura; K Sasai; N Hayabuchi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

7.  Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma.

Authors:  Tetsuya Yamaguchi; Hiroshi Takahashi; Ryuzaburou Kagawa; Ryoji Takeda; Shingo Sakata; Daisuke Nishizaki; Teruyuki Takamatsu; Yoko Iwasa
Journal:  Hepatogastroenterology       Date:  2008 May-Jun

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Authors:  Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt
Journal:  Lancet Oncol       Date:  2008-04-08       Impact factor: 41.316

10.  CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.

Authors:  Devrim Karaosmanoglu; Musturay Karcaaltincaba; Berna Oguz; Deniz Akata; Mustafa Ozmen; Okan Akhan
Journal:  Eur J Radiol       Date:  2008-05-29       Impact factor: 3.528

View more
  4 in total

1.  Small bowel intussusception due to a primary non-Hodgkin's lymphoma. An unusual presentation and clinical course.

Authors:  Nikolaos S Salemis; Evangelos Tsiambas; Christos Liatsos; Andreas Karameris; Efstathios Tsohataridis
Journal:  J Gastrointest Cancer       Date:  2010-12

2.  Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets.

Authors:  Alison K Yoder; Jillian R Gunther; Sarah A Milgrom; Mary Pham; Donald Hancock; Kelli McSpadden; John Garcia; Dragan Mirkovic; Bouthaina S Dabaja; Chelsea C Pinnix
Journal:  Pract Radiat Oncol       Date:  2019-01-29

3.  Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.

Authors:  Alison K Yoder; Jillian R Gunther; Sarah A Milgrom; Dragan Mirkovic; Loretta Nastoupil; Sattva Neelapu; Michelle Fanale; Nathan Fowler; Jason Westin; Hun Ju Lee; M Alma Rodriguez; Swaminathan P Iyer; Luis Fayad; Yago L Nieto; Chitra Hosing; Sairah Ahmed; L Jeffrey Medeiros; Joseph D Khoury; Naveen Garg; Behrang Amini; Bouthaina S Dabaja; Chelsea C Pinnix
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-09-10

4.  Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.

Authors:  Jong Bong Lee; Atheer Zgair; Jed Malec; Tae Hwan Kim; Min Gi Kim; Joseph Ali; Chaolong Qin; Wanshan Feng; Manting Chiang; Xizhe Gao; Gregory Voronin; Aimie E Garces; Chun Long Lau; Ting-Hoi Chan; Amy Hume; Tecashanell M McIntosh; Fadi Soukarieh; Mohammed Al-Hayali; Elena Cipolla; Hilary M Collins; David M Heery; Beom Soo Shin; Sun Dong Yoo; Leonid Kagan; Michael J Stocks; Tracey D Bradshaw; Peter M Fischer; Pavel Gershkovich
Journal:  J Control Release       Date:  2018-07-18       Impact factor: 9.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.